ASH Clinical News December 2016 | Page 91

exploreIDH.com

Nearly 20% of patients with
AML have an IDH mutation.

It’s time to find them.
Acute myeloid leukemia (AML) is a complex, heterogeneous disease
associated with multiple chromosomal aberrations and genomic
mutations, such as mutated isocitrate dehydrogenase (IDH) 1 and IDH2. 1-4
Data have emerged showing that IDH mutations occur in an estimated
20% of patients with AML.1,5 IDH mutations can be detected through
molecular profiling, and Patients with IDH mutations may be eligible for
ongoing clinical trials.
Test your AML patients for IDH mutations and see if they’re eligible for
a clinical trial. Learn more at exploreIDH.com.
Visit Agios at booth #4043
References: 1. Estey E, Döhner H. Acute myeloid leukaemia. Lancet. 2006;368(9550):1894-1907. 2. Burnett A, Wetzler
M, Löwenberg B. Therapeutic advances in acute myeloid leukemia. J Clin Oncol. 2011;29(5):487-494. 3. Döhner H,
Weisdorf DJ, Bloom eld CD. Acute myeloid leukemia. N Engl J Med. 2015;373(12):1136-1152. 4. Papaemmanuil E,
Gerstung M, Bullinger L, et al. Genomic classi cation and prognosis in acute myeloid leukemia. N Engl J Med.
2016;374(23):2209-2221. 5. McKenney AS, Levine RL. Isocitrate dehydrogenase mutations in leukemia. J Clin Invest.
2013;123(9):3672-3677.
© 2016 Agios Pharmaceuticals, Inc. 11/15 GL-IDH-PRNAD-049a